DORM Q1 2026 Earnings EPS Misses Estimates Stock Under Pressure ESS Q1 2026 Earnings Strong Earnings Beat Driven by Operational Efficiency Xenetic Biosciences Q2 2025 Earnings Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress ADC Therapeutics Q1 2026 Earnings EPS Beat but No Revenue Reported Stock Slips Sachem Capital Corp 800 Notes due 2027 SCCG Q4 2025 Earnings Modest EPS Beat Amid Broader Market Caution Teck Resources Q1 2026 Earnings EPS Beats Estimates by Over 53 Despite Modest Market Pullback